SCHEMBL24849394

SCHEMBL24849394

COC(=O)c1cc(Br)ncc1Nc1ccc(S(C)(C)C)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 3/20 0.36
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ CSF1R P07333 3/20 0.34
▸ MAP2K1 Q02750 2/20 0.34
▸ NUDT1 P36639 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ GAA P10253 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ YAP1 P46937 1/20 0.34
▸ TGFBR1 P36897 1/20 0.34
▸ MAP2K2 P36507 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24849417 0.87 KDM4E (0.42) DHODHCA1CA2CA9MAP2K1
SCHEMBL24848943 0.85 DHODH (0.34) DHODHCA1CA2CA9CSF1R
SCHEMBL24848964 0.85 DHODH (0.36) DHODHCA1CA2CA9CSF1R
SCHEMBL24849669 0.84 DHODH (0.36) DHODHCA1CA2CA9CSF1R
SCHEMBL23673877 0.82 MAP2K1 (0.37) DHODHCSF1RMAP2K1NUDT1ALDH1A1
SCHEMBL24849644 0.77 NUDT1 (0.33) DHODHCA1CA2CSF1RMAP2K1
SCHEMBL2025343 0.74 SOS1 (0.40) CA1CA2CA9ALDH1A1GAA
SCHEMBL24196100 0.74 KEAP1 (0.36) CA1CA2CA9CSF1RNUDT1
SCHEMBL24195914 0.74 LMNA (0.38) CA1CA2CA9ALDH1A1GAA
SCHEMBL24196144 0.71 MAP2K1 (0.35) CA1CA2CA9MAP2K1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-31 — — US disclosed
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE BRAF, NRAS, KRAS DHODH 2249/4885CA1 4751/4885CA2 3972/4885
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, NRAS, KRAS DHODH 3092/4885CA1 3182/4885CA2 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback